← Michelle L. O’Donoghue

Papers by Michelle L. O’Donoghue

Page 1 · newest first

1. ANGPTL4 Inhibition in Adults with Elevated Triglyceride LevelsNew England Journal of Medicine · 2026
2. Clear Target, Multiple Paths: Rethinking Intensive LDL-C LoweringCirculation · 2026
3. Lipoprotein (a) Concentrations Across a Global Cross‐Sectional Registry of Patients With Established Coronary Artery DiseaseJournal of the American Heart Association · 2026
4. A Lasting Legacy: Honoring the Life and Impact of Dr Eugene BraunwaldCirculation · 2026
5. A Polygenic Risk Score to Predict Incident Heart Failure Across the Spectrum of Cardiovascular RiskJournal of the American College of Cardiology · 2025
6. Antithrombotic Treatment in Transcatheter Aortic Valve ImplantationJournal of the American College of Cardiology · 2013
7. Lipoprotein(a) for Risk Assessment in Patients With Established Coronary Artery DiseaseJournal of the American College of Cardiology · 2013
8. Increasing Participation of Women in Cardiovascular TrialsJournal of the American College of Cardiology · 2021
9. Intraindividual Variability in Serial Lipoprotein(a) Concentrations Among Placebo-Treated Patients in the OCEAN(a)-DOSE TrialJournal of the American College of Cardiology · 2024
10. Beyond Short-Term RiskJournal of the American College of Cardiology · 2026
11. Fibrinolytic Therapy for Thromboembolic DiseasesJournal of the American College of Cardiology · 2025
12. A polygenic risk score predicts atrial fibrillation in cardiovascular diseaseEuropean Heart Journal · 2022
13. Early Versus Late Initiation of Evolocumab and Arterial Aneurysm Events: An Analysis of FOURIER and FOURIER-OLECirculation · 2026
14. Omega-3 Fatty Acid Biomarkers and Incident Atrial FibrillationSocio-Environmental Systems Modeling · 2023
15. Obesity-Associated Cardiovascular Risk and Benefit From PCSK9 InhibitionJournal of the American College of Cardiology · 2025
16. Small-Interfering RNA Olpasiran and Apolipoprotein B ParticlesJAMA Cardiology · 2025
17. Efficacy and Safety of Very Low Achieved LDL Cholesterol in Patients With Previous Ischemic StrokeCirculation · 2025
18. Polygenic risk score for coronary artery disease across the spectrum of atherosclerotic diseaseEuropean Journal of Preventive Cardiology · 2025
19. A polygenic risk score for peripheral artery disease and major adverse limb eventsEuropean Heart Journal · 2025
20. Statistical approaches for systematically missing covariates in individual participant data meta-analysis: insights and applications using 5 large cardiovascular trialsAmerican Journal of Epidemiology · 2025
21. Dapagliflozin in Patients Hospitalized for Heart Failure: Primary Results of the DAPA ACT HF-TIMI 68 Randomized Clinical Trial and Meta-Analysis of Sodium-Glucose Cotransporter-2 Inhibitors in Patients Hospitalized for Heart FailureCirculation · 2025
22. Overcoming Barriers to Developing and Implementing Novel Therapies for HypertensionHypertension · 2025
23. Lipoprotein(a) and Venous Thromboembolism: Association, Causality, and MedicationsThrombosis and Haemostasis · 2025
24. Ignorance is not bliss: the importance of lipoprotein(a) testingEuropean Heart Journal · 2025
25. The year in cardiovascular medicine 2024: the top 10 papers in thrombosis and antithrombotic treatmentEuropean Heart Journal · 2025
26. 2025 ACC/AHA/ACEP/NAEMSP/SCAI Guideline for the Management of Patients With Acute Coronary Syndromes: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice GuidelinesCirculation · 2025
27. Olpasiran, Oxidized Phospholipids, and Systemic Inflammatory BiomarkersJAMA Cardiology · 2025
28. Long-Term Cognitive Safety of Achieving Very Low LDL Cholesterol with EvolocumabNEJM Evidence · 2024
29. Sex differences in treatment strategies for pulmonary embolism in older adults: The SERIOUS-PE study of RIETE participants and US Medicare beneficiariesVascular Medicine · 2024
30. The Off-Treatment Effects of Olpasiran on Lipoprotein(a) LoweringJournal of the American College of Cardiology · 2024
31. Intranasal Oxytocin for ObesityNEJM Evidence · 2024
32. The year in cardiovascular medicine 2023: the top 10 papers in thrombosis and antithrombotic treatmentEuropean Heart Journal · 2024
33. Fibrinolytic Agents in Thromboembolic Diseases: Historical Perspectives and Approved IndicationsSeminars in Thrombosis and Hemostasis · 2024
34. Novel Polygenic Risk Score and Established Clinical Risk Factors for Risk Estimation of Aortic StenosisJAMA Cardiology · 2024
35. Defining Strategies of Modulation of Antiplatelet Therapy in Patients With Coronary Artery Disease: A Consensus Document from the Academic Research ConsortiumCirculation · 2023
36. Sex-Related Differences in Patient Characteristics, Risk Factors, and Symptomatology in Older Adults with Pulmonary Embolism: Findings from the SERIOUS-PE StudySeminars in Thrombosis and Hemostasis · 2023
37. Association Between Achieved Low-Density Lipoprotein Cholesterol Levels and Long-Term Cardiovascular and Safety Outcomes: An Analysis of FOURIER-OLECirculation · 2023
38. Chronic rheumatologic disorders and cardiovascular disease risk in womenSHILAP Revista de lepidopterología · 2023
39. Small Interfering RNA to Reduce Lipoprotein(a) in Cardiovascular DiseaseNew England Journal of Medicine · 2022
40. Growth differentiation factor 15 and cardiovascular risk: individual patient meta-analysisEuropean Heart Journal · 2022
41. Lipoprotein(a), cardiovascular events, and benefit of P2Y12 inhibition: insights from the PEGASUS-TIMI 54 trialEuropean Heart Journal · 2022
42. Long-Term Evolocumab in Patients With Established Atherosclerotic Cardiovascular DiseaseCirculation · 2022
43. Anticoagulation and Antiplatelet Therapy for Prevention of Venous and Arterial Thrombotic Events in Critically Ill Patients With COVID-19: COVID-PACTCirculation · 2022
44. Study design and rationale for the Olpasiran trials of Cardiovascular Events And lipoproteiN(a) reduction-DOSE finding study (OCEAN(a)-DOSE)American Heart Journal · 2022
45. Plasma Omega‐3 Fatty Acids and the Risk of Cardiovascular Events in Patients After an Acute Coronary Syndrome in MERLIN‐TIMI 36Journal of the American Heart Association · 2021
46. Comparison of the Efficacy and Safety Outcomes of Edoxaban in 8040 Women Versus 13 065 Men With Atrial Fibrillation in the ENGAGE AF-TIMI 48 TrialCirculation · 2021
47. Sex, Permanent Drug Discontinuation, and Study Retention in Clinical TrialsCirculation · 2021
48. Plasma ceramide and phospholipid-based risk score and the risk of cardiovascular death in patients after acute coronary syndromeEuropean Journal of Preventive Cardiology · 2020
49. Clinical Application of a Novel Genetic Risk Score for Ischemic Stroke in Patients With Cardiometabolic DiseaseCirculation · 2020
50. The Safety and Efficacy of Aspirin Discontinuation on a Background of a P2Y ₁₂ Inhibitor in Patients After Percutaneous Coronary InterventionCirculation · 2020